STK11 and non-small cell lung carcinoma: Specifically, KRAS-mutant NSCLC with STK11 or KEAP1 mutations tends to have a poorer prognosis, and comprehensive co-mutation analyses in KRAS-mutant NSCLC have not been conducted extensively for other ICI combination therapies except IMpower150 (57).